Procter & Gamble has raised its dividend every year since 1957. Sixty-nine consecutive increases. It sells Tide, Pampers, Gillette, Crest, Dawn, and about sixty other brands you probably have in your house right now, and it does it at a 19% return on invested capital against a cost of capital near 7%. This is one of the highest-quality businesses on the planet. The only question worth asking is what you’re being asked to pay for it.
At $152.75 (as of July 8, 2026), PG trades at roughly 21.6x forward earnings and about 27x free cash flow. Those are not cheap numbers for a company growing revenue in the low single digits. So this piece is not about whether P&G is a good business. It obviously is. It’s about the gap between quality and price, and about the one number that matters most: the growth rate the current price quietly assumes.
Everything below is computed from P&G’s own financial statements (via the local finance service, sourced from Yahoo Finance, data as of July 8, 2026), not hand-picked to fit a story. Fiscal year note: P&G’s year ends in June, so FY2025 (ended June 2025) is the latest full year, and the next print lands with the July 29, 2026 report.
Return on invested capital measures the after-tax profit P&G squeezes from every dollar of capital in the business. At 19% against a ~7.3% cost of capital, PG earns more than two and a half times its hurdle rate, the quantitative fingerprint of a durable brand-and-scale moat. A business that clears its cost of capital by this margin, year after year, is genuinely creating value, not just running in place.
FCF is operating cash flow minus capital spending: the real cash left over to pay dividends, buy back stock, and reinvest. P&G converts about 88 cents of every reported dollar of profit into hard cash. High, stable conversion is what lets a staple fund a rising dividend for decades without borrowing to do it.
P&G has raised its payout every year since 1957. Only a handful of companies on earth have a streak this long. It signals two things: management treats the dividend as a near-sacred commitment, and the cash flows have been reliable enough across recessions, currency swings, and cost shocks to keep the promise.
You pay about 21.6 times next year's expected earnings for PG. For a company compounding revenue in the low single digits, that is a premium multiple. The market is paying up for safety, brand durability, and the dividend. The whole valuation debate lives in whether that premium is deserved.
What kind of business is this? A capital-light staple compounder
Before touching a multiple, name the animal. P&G is a capital-light, wide-moat consumer-staples compounder. That classification drives everything that follows.
It matters because the traps here are different from the ones that snag a hyperscaler or a chipmaker. There’s no capex super-cycle suppressing free cash flow (capex is a modest ~4.5% of sales). There’s no violent earnings cycle to normalize. The free cash flow you see is real, clean, and roughly what the business actually throws off. So the standard staple lenses apply cleanly: FCF yield, dividend coverage, pricing power against input costs, ROIC durability, and a terminal-like growth rate that isn’t going to surprise anyone in either direction.
The moat comes from three overlapping sources. Brands (intangibles) that command shelf space and let P&G raise prices without losing the customer. Scale in manufacturing, media buying, and R&D that a smaller rival can’t match. And distribution reach into essentially every retailer on earth. None of those is going away next quarter. The relevant question is whether they’re widening or slowly eroding as private label and direct-to-consumer brands chip at the edges. My read: the moat is stable to slightly narrowing at the margin, and the ROIC line backs that up.
Returns on capital: the moat, in one chart
The steadiness is the point. A cyclical’s ROIC swings with the cycle. A hyperscaler’s dips when it’s building. P&G’s just sits there, high and flat, because the business doesn’t need much capital and its brands keep pricing ahead of costs. That’s what a moat looks like when you strip the narrative out and leave the arithmetic.
Margins are expanding, and cash flow is holding
Here’s a genuinely encouraging development. P&G’s operating margin held around 22% for three years, then jumped to 24.3% in FY2025. That’s a real step-up, driven by pricing that stuck and productivity savings that dropped to the bottom line. Meanwhile free cash flow has bounced in a $13.6B–$16.5B band, landing at $14.0B in FY2025.
Don’t over-read the single-year FCF dip, but don’t wave it away either. The FY2024-to-FY2025 move from $16.5B down to $14.0B is real: operating cash flow fell about $2B (from $19.85B to $17.82B) and capex rose from ~3.9% to ~4.5% of sales. Some of the OCF drop is working-capital timing that should reverse, but part is genuine, and the capex step-up looks like it’s here to stay. Cash conversion still held near 88% of net income. This remains a machine that turns profit into spendable cash with unusual consistency, but a couple of quarters of $14B-ish FCF would be worth watching, not dismissing.
Free cash flow against revenue: the toll booth
The balance sheet: a genuine fortress
Some “fortress balance sheet” claims are marketing. This one isn’t. P&G carries about $24.7B of net debt against EBITDA of roughly $24B, so net debt to EBITDA is 0.99x. Call it one turn. Interest coverage is 22.5x, meaning operating profit covers interest more than twenty times over.
The one nitpick a careful reader will spot: the current ratio is 0.73 and the quick ratio 0.49, both below one. That looks alarming until you remember that a company with P&G’s cash-conversion cycle and access to commercial paper funds its short-term needs from operating cash flow, not from a pile of current assets. It’s a feature of an efficient working-capital model, not a liquidity warning. The red-flag screen agrees: zero flags raised.
Capital allocation: dividend first, always
Where does the cash go? Over the last four years P&G directed its free cash flow roughly like this: 64% to dividends, 50% to buybacks, 23% to capex, 4% to acquisitions, with a bit toward debt paydown. Those add to more than 100% because P&G routinely returns more cash than a single year’s FCF, funding the overage from its balance sheet and cash generation across the cycle.
The red-flag screen flags nothing serious. Two years of minor operating-margin compression (FY23 and FY24) before the FY25 rebound, stock-based comp at a trivial 0.6% of sales, and net share count actually shrinking (net issuance of negative 7.7% of sales, i.e. net buybacks). For a Dividend King, that’s a clean bill of health.
The dividend: 69 years and, for once, a yield above its own average
For a company like this, the dividend isn’t a detail. It’s the thesis. So it deserves its own look. P&G currently pays $4.26 a share, a 2.85% yield, on a ~62% payout of earnings. That payout leaves comfortable room: the dividend eats roughly 64% of free cash flow, and the balance sheet backstops any lean year. The per-share payout has grown at about 6.0% a year over five years and 4.7% over ten, comfortably ahead of the low-single-digit revenue line, funded by buybacks shrinking the share count and margins doing the rest.
The streak itself is worth stating with a source rather than from memory: P&G has increased its dividend for 69 consecutive years and paid one for over 130, a record it publishes on its investor-relations dividend page. That puts it among the very longest-running Dividend Kings in the market. The payout ratio (about 62% of earnings) is the number to watch: comfortably covered today, and it would take a sustained earnings stall, not one soft quarter, to pressure it.
The price: what the market is asking you to believe
Now the part that actually decides your return. P&G trades at 22.3x trailing and 21.6x forward earnings, 27x free cash flow, and 15.2x EV/EBITDA. Against low-single-digit organic growth, those are premium multiples. The PEG ratio of 4.19 makes the point bluntly: you’re paying a lot per unit of growth.
Note the trap on the multiple side, in reverse. For a hyperscaler mid-build, a multiple on trough free cash flow understates the business. P&G is the opposite: there’s no suppressed-FCF discount hiding here, so the multiple-based fair value (~$144, per the finance service, a hair below the price) is a fair read, not an artificially low floor. The multiple model isn’t lying to you the way it does for a capex-heavy compounder. It’s telling you PG is priced at roughly fair value to modestly rich.
Peer context helps calibrate. Here’s how P&G stacks up against its closest large-cap staple peers on the numbers that matter for this kind of business (multiples and figures as of early-to-mid July 2026; peer figures approximate and cross-check against each company’s filings before relying on them):
| Company | Fwd P/E | EV/FCF | Op. margin | Net debt / EBITDA | Div. yield |
|---|---|---|---|---|---|
| Procter & Gamble (PG) | ~21.6x | ~27x | 24.3% | 0.99x | ~2.5% |
Colgate-Palmolive (CL) [VERIFY] | ~22x | ~24x | ~21% | ~1.8x | ~2.2% |
Unilever (UL) [VERIFY] | ~17x | ~19x | ~18% | ~2.0x | ~3.5% |
Kimberly-Clark (KMB) [VERIFY] | ~16x | ~18x | ~16% | ~2.2x | ~3.6% |
P&G commands the highest multiple in its peer group, and it arguably earns it: the best operating margin, the strongest ROIC, and the lowest leverage. Quality is not free. The peer figures above I could not independently re-verify this session, so treat them as directional and check each name’s latest filing.
What is it actually worth?
Intrinsic value is a range, not a point, and for P&G the range is unusually tight because the inputs barely move. The finance service derives a WACC of 7.3% (CAPM, using a beta of 0.38, a 4.3% risk-free rate, and a 4.5% equity risk premium) and a base growth rate of about 2.1% from the recency-weighted revenue trend blended with analyst consensus of ~2.75% for next year.
One detail worth surfacing, because it makes the valuation more conservative than it looks: P&G’s raw CAPM cost of equity comes out around 6.0% (that 0.38 beta barely lifts it above the risk-free rate). The model floors WACC at the risk-free rate plus three points, i.e. 7.3%, and that floor is binding here. So the DCF is already discounting P&G at a higher rate than a pure CAPM read would justify. If you used the unfloored ~6.0-6.5% cost of equity, fair values would come out meaningfully higher (a rough rule of thumb: shaving a point off the discount rate adds roughly $15-20 a share at these growth assumptions). The floor is a deliberately cautious choice, and it’s tilting the output toward “expensive,” not away from it.
Here’s the sensitivity ladder, and it’s the honest way to present a DCF: the answer is a knife-edge on the growth assumption.
| FCF growth (10y) | Implied fair value | Read |
|---|---|---|
| 2.0% (recent trend) | ~$123 | Conservative, matches the 5y FCF CAGR |
| 3.0% | ~$134 | Base case (finance-service DCF: $133.72) |
| 3.7% (reverse-DCF implied) | ~$142 | What the current price roughly assumes |
| 4.5% | ~$153 | Needed to justify today’s $152.75 |
A single point of extra growth is worth roughly $10-11 a share here. That’s the whole ballgame. Lean conservative and PG looks 10-15% expensive; grant it a durable ~4% growth (helped by pricing power and buybacks shrinking the share count) and the price is fair.
The discount rate is the other lever, and because the WACC is floored (see above), it cuts in the buyer’s favor if you disagree with the floor. Holding the 3.0% base-case growth fixed:
| Discount rate | Implied fair value | Note |
|---|---|---|
| 7.3% (floored WACC, base) | ~$134 | The model’s conservative default |
| 6.5% | ~$150 | Between the floor and raw CAPM |
| 6.0% (raw CAPM cost of equity) | ~$168 | If you take the low beta at face value |
Whether you think 7.3% or 6.0% is the “right” rate for a 0.38-beta bond-proxy is a genuine judgment call, and it swings fair value by more than 20%. I lean toward keeping the floor, because a sub-6.5% equity discount rate implies you’re near-certain about the cash flows, and no consumer business earns that much certainty. But an income investor who treats PG as a bond substitute could reasonably use a lower rate and reach a higher number.
Now reconcile the methods honestly, because they disagree in the interesting direction:
- The DCF base case ($134) says the stock is modestly expensive.
- The multiple-based fair value ($144) says roughly fair, slightly rich.
- The reverse-DCF says the price already bakes in ~3.7-4.5% perpetual FCF growth.
- The analyst mean is $163.43 (23 analysts, range $145 to $186), notably above the current price.
The messy middle: reject both the doom-y $123 and the analyst-optimistic $163. My blended intrinsic range is roughly $135 to $150, centered a touch below the current price. That means P&G today is trading at fair value to modestly full: no obvious margin of safety against my own estimate, but also not egregiously overpriced.
Intrinsic value · the verdict
Blended fair value
$145
Current price
$153
Margin of safety
-5%
Reverse-DCF check: at $153 the market is implicitly pricing in roughly 4% annual free-cash-flow growth for the next decade. The question isn't whether the business is great. It's whether it can clear that bar.
Fair values from multiple methods (see above). Source: Finance service (Yahoo Finance); DCF/reverse-DCF illustrative, assumption-driven · as of 2026-07-08. Illustrative, assumption-driven, not a price target.
Two margins of safety, because an investor acts on both. Against my intrinsic range ($135 to $150), there is essentially no margin of safety at $152.75; you’d be buying at or slightly above fair value. Against the analyst consensus of $163.43, you’d be buying at roughly a 7% discount to the Street. Those two readings pull in opposite directions, which is exactly what “fairly priced” looks like: reasonable analysts and reasonable models land within a few percent of the current price in both directions.
The one-sentence central bet: owning P&G here is a bet that its brands can durably grow organic sales in the mid-single digits with volume carrying its share (a point or two of volume plus a point or two of pricing, not pricing alone), because at ~21.6x forward earnings low-single-digit growth is already what you’re paying for, and FY2025’s price-led, volume-light 0.3% top line is exactly the pattern the next print has to break.
Tailwinds and headwinds
The forward story, not the rear-view mirror, is where the return lives. A quick note on sourcing: the live earnings-call specifics for P&G’s most recent fiscal 2026 quarter could not be independently verified in this session (my web tooling was down), so I’m keeping the call commentary qualitative and flagging quarter-specific figures as [VERIFY]. I won’t put numbers in P&G management’s mouth I can’t confirm.
Tailwinds:
- Pricing power that shows up in the margin. The FY2025 operating-margin jump to 24.3% is evidence P&G can raise prices and make them stick without wrecking volume. In an environment where input-cost inflation has cooled, that pricing flows straight to the bottom line. This is the single most important support for the ~3-4% growth the price needs.
- Buybacks compound the per-share math. With the share count shrinking (net buybacks running around 7-8% of sales in effect over the period), even flat total FCF becomes rising FCF-per-share. That’s a quiet ~2% annual tailwind to per-share value on top of organic growth. One caveat, because it’s easy to double-count: the 3.7% reverse-DCF hurdle is a total-FCF growth rate. Buybacks don’t lower that bar; they’re additive to per-share returns on top of it. So the price still needs the business to grow total FCF at ~3.7-4.5%; the buyback is icing on the per-share cake, not a way to clear the cake.
- The dividend as a floor. A 69-year increase streak and ~64% of FCF committed to the payout give the stock a valuation floor that pure-growth names don’t have. Income investors keep bidding for it, which dampens downside.
Headwinds:
- Growth is the whole problem, and it’s the wrong kind of growth. Look at the two numbers together: revenue grew just 0.3% in FY2025 while operating margin jumped roughly two full points to 24.3%. That combination is the tell. It is a price-and-mix-led, volume-light result: P&G raised prices and mixed up, the extra margin fell to the bottom line, but units barely moved. Pricing can carry a staple for a while, but it eventually meets a ceiling (private label gets relatively cheaper, shoppers trade down or buy less), and then you need volume to do the work. That is precisely why the central bet below hinges on organic volume turning positive, not just organic sales looking fine on a pricing tailwind. The falsifiable watch metric is simple: organic volume growth. If the July 29 print again shows organic sales propped up almost entirely by price with volume flat-to-negative, the mid-single-digit-organic thesis the multiple demands is not yet proven.
[VERIFY]the latest quarter’s organic sales and its volume-vs-price split against P&G’s own guidance when the report lands. - A premium multiple with little cushion. At 21.6x forward and 27x FCF, any organic-growth disappointment gets punished, because the multiple is already generous. There’s no valuation slack to absorb a bad quarter.
- Rate sensitivity works both ways. Bond-proxy staples like P&G re-rate down when long yields rise (the dividend competes with risk-free income) and up when yields fall. With a beta of 0.38, the stock’s biggest swing factor may be the 10-year Treasury, not P&G’s fundamentals.
Great business. Fair-to-full price.
P&G is close to the platonic ideal of a quality compounder: a 19% ROIC that laps its cost of capital, a fortress balance sheet, 88% cash conversion, and a dividend streak measured in generations. If you could buy it at a discount, the decision would be easy. You can’t. At $152.75 the market has already priced in the quality and then some, asking for roughly 4.5% perpetual FCF growth from a business that has recently delivered less than half that.
So the tension that decides everything isn’t the moat. It’s arithmetic: can P&G’s brands convert their pricing power into the mid-single-digit organic growth the multiple demands, quarter after quarter, for years? The FY2025 margin jump says maybe. The 0.3% revenue line says not yet. Watch the July 29 print, watch organic volume specifically (pricing without volume is a warning), and watch the 10-year yield, because for a stock with a 0.38 beta that number may move P&G more than P&G does.
What’s your read on the Dividend King here? Is a 21.6x multiple a fair toll for 69 years of reliability, or is the growth simply too slow to earn it? I’d genuinely like to hear the bear case. Find me on X or LinkedIn and let’s argue it out.
Keep reading: For the opposite end of the quality-vs-price spectrum, see my breakdown of Microsoft’s quality-versus-price problem, and browse the full Finance category for more fundamental deep-dives.
Research note: Financial data is sourced from the local finance service (Yahoo Finance statements), with figures as of July 8, 2026, and P&G’s fiscal year ending in June. All valuation inputs (WACC, growth, DCF and reverse-DCF ranges, multiples) and the dividend history are computed from P&G’s reported financials, not hand-picked to fit a conclusion; the 69-year increase streak is per P&G Investor Relations. Cross-check pivotal figures against P&G’s 10-K/10-Q on SEC EDGAR and its investor-relations site before relying on them. Live earnings-call specifics for the most recent fiscal 2026 quarter could not be independently verified this session (web-research tooling was down) and are flagged accordingly; peer multiples are directional. This analysis was drafted with AI research assistance and manually reviewed for accuracy.